KRAS Breakthrough & HTA Realities

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, health economist, and it's great to have you with us today.

SaraAnd I'm Sara, market access strategy. Always good to be here — and I'll say, the KRAS approval and NICE threshold shift are both keeping me up tonight.

MarcusSame here. We're looking at the FDA's accelerated approval for a novel KRAS inhibitor in NSCLC — first of its kind, which will test the RWE evidence generation framework. Then the EMA's new SMA gene therapy — the third in class, but with a safety profile that could change the value proposition. And NICE's threshold consultation — a direct response to the high-cost therapy wave. Finally, JCA capacity constraints — the reality check on cross-border collaboration.

SaraThat NICE consultation is critical — the budget impact question at £50,000 per QALY is one the field hasn't fully worked out yet.

MarcusExactly. Let's get into it.

MarcusStarting with the FDA accelerated approval for that KRAS inhibitor in NSCLC. This is huge — first targeting a previously undruggable mutation. Based on objective response rate and duration in a single-arm trial, but the FDA is requiring confirmatory trials. What strikes me is how this forces the industry to rethink accelerated approval evidence pathways post-2022 FDA guidance.

SaraAbsolutely. And what gives me pause is the confirmatory trial design. The FDA's insistence on OS or PFS endpoints in post-acceleration trials could create massive RWE gaps for therapies where placebo controls are ethically untenable. I wonder if that's the full picture though — the KRAS inhibitor's label doesn't specify comparator arms for confirmatory studies, which could leave payers questioning real-world value.

MarcusThat's a fair point. The absence of comparator arms in the approval letter does create ambiguity for HTA bodies. But what's interesting is the precedent this sets for other undruggable targets. The RWE evidence generation framework will be tested here, especially since the trial population was heavily pre-treated.

SaraRight, and from the payer side, the budget impact could be substantial if this becomes first-line. The single-arm data shows 40% response rates, but without a comparator, cost-effectiveness models will struggle. I keep coming back to how this mirrors the CAR-T experience — accelerated approval followed by real-world evidence battles.

MarcusExactly. And the FDA's requirement for confirmatory trials within 5 years means the clock is ticking for generating that RWE. This will force companies to integrate RWE earlier in development, which aligns with the FDA's 2023 RWE framework. But the challenge will be ensuring RWE captures the same population as the accelerated approval trial.

SaraThat's the million-dollar question. If the confirmatory trial enrollment diverges from real-world use, the evidence gap widens. And payers will scrutinize that gap closely. What strikes me is how this approval underscores the tension between speed and robustness in oncology evidence generation.

MarcusAgreed. Now, shifting to the EMA's CHMP recommendation for the third SMA gene therapy. Different viral vector, different dosing, and notably reduced hepatotoxicity risk. This could reshape the cost-effectiveness calculus in Europe.

SaraAnd that reduced hepatotoxicity is a game-changer. The existing SMA therapies carry significant monitoring costs for liver function, which NICE has factored into previous appraisals. If this new therapy reduces that burden, the cost-effectiveness profile shifts dramatically — potentially making it more attractive even at a similar price point.

MarcusThat's one read — I'd frame it slightly differently. The CHMP noted the reduced hepatotoxicity, but didn't quantify it. For HTA bodies, the absence of comparative safety data against existing therapies creates uncertainty. The value proposition hinges on real-world safety data post-launch. What's striking here is the precedent for using safety differences as a value driver in gene therapy appraisals.

SaraAbsolutely. And the fact that it's the third SMA gene therapy in the EU means payers have established benchmarks. But the dosing regimen difference could impact long-term budget modeling. I wonder how NICE will handle the safety claims without head-to-head data. They typically require comparative evidence for such claims.

MarcusThat's fair, though I think payers would see it differently. The reduced hepatotoxicity could lower overall treatment costs by reducing hospitalizations and monitoring. But the methodological challenge is quantifying that benefit. NICE's recent willingness to accept surrogate endpoints in rare diseases might come into play here.

SaraTrue, but the budget impact remains significant. Even with reduced hepatotoxicity, gene therapies cost millions. The threshold consultation we're discussing next makes this even more relevant. This new therapy's value will be tested against both clinical outcomes and system-wide cost savings.

MarcusNow, NICE's threshold consultation — proposing to raise the upper threshold to £50,000 per QALY. This is a direct response to high-cost, high-impact therapies in oncology and rare diseases. What connects to something I keep coming back to is how this could accelerate access for breakthrough technologies but create budgetary tensions.

SaraThe budget impact question is exactly what worries me. At £50,000, technologies that previously failed at £30,000 could get approved, but the opportunity cost increases. The NHS has finite resources — every £50,000 spent on one therapy is £50,000 not spent elsewhere. I'd push back slightly on that — the consultation doesn't address how this affects the cost-effectiveness threshold for non-innovative therapies.

MarcusThat's a valid point. The consultation focuses on highly innovative technologies but leaves the standard threshold unchanged. This creates a two-tiered system that could complicate evidence strategies. What's interesting is how this mirrors the EMA's PRIME designation — innovation as a distinct value driver. But the methodological challenge is defining "highly innovative" consistently across HTA bodies.

SaraAbsolutely. And the consultation doesn't specify how this would interact with the end-of-life criteria. If a therapy qualifies for both £50,000 and end-of-life adjustments, the effective threshold could be even higher. That's one of the stories where the practical implementation details will determine whether this truly improves access or just increases costs.

MarcusExactly. Finally, the JCA capacity constraints — a 40% increase in requests since inception, leading to delays. They're implementing a triage system to prioritize requests with highest cross-jurisdictional alignment potential. What strikes me is how this exposes the structural limitations of the JCA program.

SaraAnd the triage system is a pragmatic response, but it raises equity concerns. Smaller companies with fewer resources might struggle to navigate the prioritization criteria. The 40% surge shows the program's success, but the delays could frustrate sponsors who rely on JCA for HTA readiness. I wonder if that's the full picture though — the JCA's capacity constraints might actually improve the quality of scientific advice by forcing more focused requests.

MarcusThat's one perspective — I'd frame it slightly differently. The delays could undermine the JCA's goal of early alignment. Sponsors might bypass JCA scientific advice and proceed with separate national submissions, fragmenting evidence generation. The part that gives me pause is how this impacts the timeline for oncology assessments, where timely access is critical.

SaraRight, and from the payer side, inconsistent timing across jurisdictions could lead to divergent appraisals. The triage system needs to balance speed with inclusivity. What connects to today's other topics is how this capacity crunch interacts with the KRAS approval and NICE threshold shift — all are evidence generation bottlenecks in a high-demand environment.

MarcusExactly. The JCA challenges highlight the need for better resource planning, but also for more efficient evidence generation methods. This is one of those stories where the operational realities of HTA are colliding with the pace of innovation.

SaraA lot to think about today. I'll be watching how NICE's threshold consultation evolves — particularly whether it addresses the budget impact trade-offs explicitly.

MarcusSame — and for me the thread running through today is the tension between innovation access and system sustainability. All these stories are forcing us to rethink evidence generation and appraisal frameworks.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.